Gill Lisa, Jones Cresta W
Department of Obstetrics, Gynecology and Women's Health, Division of Maternal-Fetal Medicine, University of Minnesota, Minneapolis, Minnesota.
Obstet Gynecol. 2021 May 1;137(5):894-896. doi: 10.1097/AOG.0000000000004367.
Studies evaluating the safety and efficacy of currently available vaccines for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) do not include pregnant participants. No data are available to counsel on vaccine safety and potential for neonatal passive immunity.
A 34-year-old multigravid patient working in health care received the Pfizer-BioNTech (BNT162b2) mRNA vaccine for SARS-CoV-2 in the third trimester of pregnancy. Uncomplicated spontaneous vaginal delivery of a female neonate with Apgar scores of 9 and 9 occurred at term. The patient's blood as well as neonatal cord blood were evaluated for SARS-CoV-2-specific antibodies. Both the patient and the neonate were positive for antibodies at a titer of 1:25,600.
In this case, passage of transplacental antibodies for SARS-CoV-2 was shown after vaccination in the third trimester of pregnancy.
评估目前可用的严重急性呼吸综合征冠状病毒2（SARS-CoV-2）疫苗安全性和有效性的研究未纳入孕妇。尚无数据可用于指导疫苗安全性及新生儿被动免疫的可能性。
一名34岁从事医疗保健工作的多产妇在妊娠晚期接种了辉瑞-生物科技公司（BNT162b2）的SARS-CoV-2 mRNA疫苗。足月时顺利经阴道自然分娩一名阿氏评分均为9分的女婴。对患者血液以及新生儿脐带血进行了SARS-CoV-2特异性抗体检测。患者和新生儿抗体滴度均为1:25,600，呈阳性。
在此病例中，显示妊娠晚期接种疫苗后出现了SARS-CoV-2经胎盘抗体传递。
